Ramsay

Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening

Retrieved on: 
Tuesday, September 12, 2023
Karolinska Institute, Partnership, Therapy, Ramsay, Radiology, Woman, Research, CDR, Guideline, Patient, Reading, Cancer, Hospital, AI, European Society of Radiology, FDA, Breast cancer, Medical imaging

"This prospective study lays the groundwork for the widespread adoption of AI in breast cancer screening by filling the role of one radiologist, which in turn can reduce medical costs and lead to healthcare reimbursement."

Key Points: 
  • "This prospective study lays the groundwork for the widespread adoption of AI in breast cancer screening by filling the role of one radiologist, which in turn can reduce medical costs and lead to healthcare reimbursement."
  • Conducted from April 1, 2021, to June 9, 2022, this study meticulously analyzed 55,581 breast cancer screening cases in real-world clinical settings.
  • Based on the contract, Lunit has integrated Lunit INSIGHT MMG, marking the first-ever actual implementation where AI replaces one of the two human readers in breast cancer screening.
  • "This study signifies a milestone in healthcare, ushering in an era where AI seamlessly complements and elevates the standards of breast cancer screening.

Study Validates Lunit AI as a Game-Changer, Poised to Replace One Human Reader in Breast Cancer Screening

Retrieved on: 
Monday, September 11, 2023
Karolinska Institute, Partnership, Therapy, Ramsay, Radiology, Woman, Research, CDR, Guideline, Patient, Reading, Cancer, Hospital, AI, European Society of Radiology, FDA, Breast cancer, Medical device, Medical imaging

SEOUL, South Korea, Sept. 11, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, is spearheading a transformative change in breast cancer screening, bolstered by groundbreaking findings from a prospective study led by Dr. Fredrik Strand at the Karolinska Institutet, Sweden, involving over 50,000 women.

Key Points: 
  • "This prospective study lays the groundwork for the widespread adoption of AI in breast cancer screening by filling the role of one radiologist, which in turn can reduce medical costs and lead to healthcare reimbursement."
  • Conducted from April 1, 2021, to June 9, 2022, this study meticulously analyzed 55,581 breast cancer screening cases in real-world clinical settings.
  • Based on the contract, Lunit has integrated Lunit INSIGHT MMG, marking the first-ever actual implementation where AI replaces one of the two human readers in breast cancer screening.
  • "This study signifies a milestone in healthcare, ushering in an era where AI seamlessly complements and elevates the standards of breast cancer screening.

SLAM Vends Gold Claim To Puma

Retrieved on: 
Thursday, March 10, 2022
National instrument, Commercial Product Assurance, Company, SEDAR, Gold, Bathurst, Ramsay, Private placement, News, Risk, Menneval, Vein, GLOBE, Mount Uniacke, Nova Scotia, Sale, NSR, Private placement life insurance, Jake Lee, Williams Brook, Program, CEO, Gold Brook Covered Bridge, National Instrument 43-101, Agreement, Cryptocurrency, Miminiska Airport, Property, Bathurst Mining Camp, SLAM

The Ferguson Brook mineral claim comprises 42 claim units covering 912 hectares of prospective land adjacent to Pumas Williams Brook gold project.

Key Points: 
  • The Ferguson Brook mineral claim comprises 42 claim units covering 912 hectares of prospective land adjacent to Pumas Williams Brook gold project.
  • SLAM owns the Ramsay and Benjamin River gold properties both located in the same geological domain as Pumas Williams Brook gold discoveries.
  • The Company owns the Gold Brook, Birch Lake gold and Wilson Brook gold properties on similar structures in central New Brunswick.
  • SLAM owns the Keezhik and Miminiska gold projects in Ontario and the Mount Uniacke gold project in Nova Scotia.

Ramsay Générale de Santé Deploys Elsevier's ClinicalKey

Retrieved on: 
Wednesday, April 17, 2019
Health, Articles, ClinicalKey, Evidence-based medicine, Healthcare software, Elsevier, Clinic, Ramsay

PARIS, April 17, 2019 /PRNewswire/ --Ramsay Gnrale de Sant, a leader in its sector, is the first private hospital in France to deploy ClinicalKey , a clinical knowledge solution from Elsevier , the global information analytics business specializing in science and health.

Key Points: 
  • PARIS, April 17, 2019 /PRNewswire/ --Ramsay Gnrale de Sant, a leader in its sector, is the first private hospital in France to deploy ClinicalKey , a clinical knowledge solution from Elsevier , the global information analytics business specializing in science and health.
  • More than 1,000 practitioners of the Ramsay Gnrale de Sant Group in France participate in research work and represent the first community of private sector researchers in France," said Dr. Stphane Locret, Research and Education Director of Ramsay Gnrale de Sant.
  • The deployment of ClinicalKey at Ramsay Gnrale de Sant will provide researchers with a reliable, relevant and comprehensive resource to support and strengthen their publications.
  • Ramsay Gnrale de Sant offers almost all medical and surgical care in three jobs: general hospitals (medicine surgery obstetric), follow-up care and rehabilitation clinics, mental health.